Trial
NCT02760615
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Colitis, Ulcerative
Intervention
Caffeine
Why stopped
No enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-27